Summary
39 / 100 · Bulios Score
Valuation 100Growth 0Profitability 0Quality 15Debt 77Stability 55
What speaks for it
- The price moves less than the market (beta 0.65).
What to watch
- Revenue fell by 19% a year over the last 3 years.
- The company made a loss over the last 12 months.
- It missed profit estimates 6 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (AUD)
2022202320242025202620272028
Diluted EPS (AUD)
2022202320242025202620272028
- Analyst estimate
Revenue fell by 11% a year over 5 years. Over the last 3 years it fell by 19% a year.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $749.9M
Debt $4.68B
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk20212022202320242025
- Yield
- 5.67%
- Raised in a row
- 1 year
You receive $0.11 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.